GeneDx Holdings/$WGS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About GeneDx Holdings
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
- Ticker
- $WGS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,300
- Headquarters
- Stamford, United States
- Website
- www.genedx.com
GeneDx Holdings Metrics
BasicAdvanced
$2B
-
-$3.64
2.01
-
Price and volume
Market cap
$2B
Beta
2.01
52-week high
$170.87
52-week low
$32.21
Average daily volume
759K
Financial strength
Current ratio
3.301
Quick ratio
2.896
Long term debt to equity
0.662
Total debt to equity
0.685
Interest coverage (TTM)
-20.00%
Profitability
EBITDA (TTM)
-33.695
Gross margin (TTM)
69.38%
Net profit margin (TTM)
-23.40%
Operating margin (TTM)
-13.13%
Effective tax rate (TTM)
-0.06%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-7.89%
Return on equity (TTM)
-40.80%
Valuation
Price to revenue (TTM)
4.263
Price to book
8.09
Price to tangible book (TTM)
19.52
Price to free cash flow (TTM)
-25.556
Free cash flow yield (TTM)
-3.91%
Free cash flow per share (TTM)
-2.594
Growth
Revenue change (TTM)
25.42%
Earnings per share change (TTM)
-7,610.63%
3-year revenue growth (CAGR)
24.33%
3-year earnings per share growth (CAGR)
-49.77%
What the Analysts think about GeneDx Holdings
Analyst ratings (Buy, Hold, Sell) for GeneDx Holdings stock.
Analyst projections of the future price of GeneDx Holdings stock.
Bulls say / Bears say
Exome and genome test volumes rose 32% year on year in the second quarter, while their revenue grew 17%; GeneDx also returned to adjusted profitability and maintained its full-year revenue guidance. This points to strong demand and a path to scale if execution holds. (GeneDx)
Coverage for genome testing expanded to 87% of commercial lives, up from 47% in the prior quarter, and 39 state Medicaid programmes now cover exome or genome testing. If GeneDx can turn these policy gains into paid claims, they could support future revenue growth. (GeneDx)
A Seattle Children’s study found a 35% diagnostic yield from rapid genome sequencing across more than 1,000 paediatric inpatients, supporting use beyond intensive-care settings. Broader hospital adoption could open a larger clinical market for GeneDx’s testing. (GeneDx)
Only about 32% of outpatient genome claims were being collected in the second quarter, down from 43% a year earlier, despite wider payer coverage. Administrative hurdles and slow claims processing mean rising test volumes may not translate into cash quickly. (Investing.com)
GeneDx cut its 2026 revenue outlook after first-quarter results and recorded a $31.3 million impairment linked to its Fabric Genomics business. That raises questions about acquisition execution and the reliability of earlier growth expectations. (SEC)
Whole-genome tests cost nearly twice as much to produce as exome tests, and genome reimbursement rates are lower. A shift towards genome testing could therefore keep pressure on unit economics even as volumes grow. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
GeneDx Holdings Financial Performance
Revenues and expenses
GeneDx Holdings Earnings Performance
Company profitability
Upcoming events
No upcoming events
GeneDx Holdings News
AllArticlesVideos
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
Business Wire22 hours ago
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
Business Wire3 weeks ago
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Benzinga2 months ago
Funds containing GeneDx Holdings
Fund name | Fund size | $WGS weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.16% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.16% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.16% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.